RxDoctor Payments Data

Constance Olatidoye, MD

Psychiatry · Wilmington, NCNPI 1346300332

Payments from drug & device makers

$1,460in general payments, 2019–2025

Across 44 payments — averaging $33.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$480
  • Alkermes, Inc.$266
  • Otsuka America Pharmaceutical, Inc.$163
  • E.r. Squibb & Sons, L.L.C.$122
  • Indivior Inc.$102
  • AbbVie$88
  • plus $238 from 6 others

What the payments were for

  • Food & beverage$1,29989%
  • Education$16111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,460 in reported general payments places this provider in the 75th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$27,517
Medicare patients
65
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate113$544,419
Abilify MaintenaAripiprazole55$211,420
Invega TrinzaPaliperidone Palmitate14$154,594
Abilify AsimtufiiAripiprazole12$69,342
LybalviOlanzapine/Samidorphan Malate30$49,617
Risperdal ConstaRisperidone Microspheres16$26,111
RexultiBrexpiprazole15$22,242
TrintellixVortioxetine Hydrobromide20$9,684
Paliperidone ErPaliperidone66$8,507
Chlorpromazine Hcl22$7,921
Asenapine Maleate15$3,996
Divalproex Sodium ErDivalproex Sodium102$3,368
Haloperidol Decanoate54$2,817
Benztropine Mesylate207$2,545
Quetiapine Fumarate143$2,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$60$725,124143 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti$163$303,00582 claims
Alkermes, Inc.Lybalvi$266$49,61730 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$13$9,68420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →